Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Generic Reviews: Would Pre-Submission Meetings Be Better Than Six-Month Priority Review?

Mar 06 2017

• By Derrick Gingery

Handshake of businessmen

Related Content

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Apr 25 2016

PDUFA V 'Program' First-Cycle Approval Rates Significantly Higher For All Applications

Dec 13 2016

REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing

Mar 03 2017

Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA

Mar 03 2017

US FDA May Find Relief From Trump's Hiring Freeze

Feb 02 2017

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

Oct 26 2016

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Oct 24 2016

Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review

Feb 03 2017

Additional Topics

United States Generic Drugs Pricing Debate Regulation Legislation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window